Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease
and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe
loss of neurons. There are no full proof cures for these diseases, and only medicines are
available that can alleviate some of the symptoms. Developing effective treatments for the
NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which
modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have
demonstrated promising neuroprotective activity mediated by various systems. It can form the
basis for elaboration of agents which will be useful both for the alleviation of symptoms of
NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration.
The further developments including detections of monoterpenoids and their derivatives
with high neuroprotective or neurotrophic activity as well as the results of qualified clinical
trials are needed to draw solid conclusions regarding the efficacy of these agents.
Keywords: Acetylcholinesterase inhibitors, Alzheimer's disease, cannabinoids, Huntington's disease, monoterpenes,
monoterpenoids, neuroprotective activity, Parkinson's disease.
Rights & PermissionsPrintExport